1. This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies. Learn More.
  2. Dear Guest, we realise advertising is annoying, it is however necessary to help us be a sustainable resource for all, if you want to go advert free then please use the following link to subscribe for £5 a month: Click here
    Dismiss Notice

Astrazeneca share chat

Discussion in 'General Share Chat' started by http://www.londonstockexc, Jul 30, 2015.

  1. http://www.londonstockexc

    http://www.londonstockexc Guest Unregistered User

    Reputation:
    0
  2. http://www.londonstockexc

    http://www.londonstockexc Guest Unregistered User

    Reputation:
    0
  3. http://www.londonstockexc

    http://www.londonstockexc Guest Unregistered User

    Reputation:
    0
  4. http://www.londonstockexc

    http://www.londonstockexc Guest Unregistered User

    Reputation:
    0
  5. http://www.londonstockexc

    http://www.londonstockexc Guest Unregistered User

    Reputation:
    0
  6. Mongoose82

    Mongoose82 A Legendary Member

    Messages:
    977
    Reputation:
    40
    This is from Beaufort's note on ResearchTree, it's available for free

    https://www.research-tree.com/company/GB0009895292

    "The aforementioned updates are mixed for AstraZeneca. The successful trial of Faslodex 500mg offers earlier treatment options to post-menopausal women with HR+ locally advanced or metastatic breast cancer. The drug has more than 10 years of clinical evidence and was recently approved by FDA for use in combination with palbociclib in the treatment of women with hormone-receptor-positive, humanepidermal-growth-factor-receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC). On the other hand, disapproval of AstraZeneca's new drug (ZS-9) for high potassium levels due to a manufacturing issue is a major setback. AstraZeneca paid US$2.7bn for ZS Pharma to gain access to the drug. Moreover, many of its drugs are in the development phase. AstraZeneca has been facing certain growth-related issues, as some of its key drugs are approaching patent expiry. In view of the mixed outlook surrounding the company, we maintain..."
     

Share This Page